Physician profile
Michael Bradshaw
NPI 1104311539
$9,872.08
in general payments reported to CMS, 2019-2025
23 companies · $4,008 in 2025
The $4,008 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $723 · 2023: $2,954 · 2024: $2,187 · 2025: $4,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,972 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,971.88 |
| Education | $177.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,527.72 | 2022-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,205.77 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $1,118.89 | 2022-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $916.56 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $846.01 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $738.99 | 2022-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $696.29 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $531.41 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $448.10 | 2024-2025 | Cobenfy |
| Corium, LLC | $419.49 | 2023-2025 | Azstarys |
| Lundbeck LLC | $252.00 | 2023-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $219.34 | 2025 | Qelbree |
| Merck Sharp & Dohme LLC | $213.71 | 2022-2023 | Belsomra |
| Tris Pharma INC | $174.57 | 2022-2025 | Dyanavel Xr, Onyda Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $124.33 | 2022-2025 | Trintellix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $112.76 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Neurocrine Biosciences, INC. | $93.28 | 2024-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $64.94 | 2023 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $58.98 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $47.03 | 2022-2025 | Adzenys Xr-Odt |
| Lilly USA, LLC | $28.82 | 2025 | Kisunla |
| Janssen Biotech, INC. | $18.25 | 2023 | |
| Luye Pharma (USA) LTD. | $14.84 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bradshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.